| Acetyl hexapeptide 38 |
Acetyl hexapeptide 38 |
1400634-44-7 |
| SJA710-6 |
SJA710 6; SJA710-6; SJA-710-6; SJA 710-6 |
1397255-09-2 |
| G-36 |
G-36;G36;G 36 |
1392487-51-2 |
| JD-5037 |
JD-5037 |
1392116-14-1 |
| N2-(7-Chloro-4-quinolinyl)-N1-[2-[(7-chloro-4-quinolinyl)aMino]ethyl]-N1-Methyl-1,2-ethanediaMine |
LYS05 |
1391426-22-4 |
| trilaciclib |
曲拉西利 |
1374743-00-6 |
| 2,9-Diazaspiro[5.5]undecan-1-one, 2-(1H-indol-3-ylMethyl)-9-(4-Methoxy-2-pyriMidinyl)- |
2,9-Diazaspiro[5.5]undecan-1-one, 2-(1H-indol-3-ylMethyl)-9-(4-Methoxy-2-pyriMidinyl)- |
1373765-19-5 |
| 1,3-Dibromo-5-fluoro-4-methoxy-6-methyl-2-nitrobenzene |
1,3-二溴-2-硝基-4-甲氧基-5-氟-6-甲基苯 |
1357103-68-4 |
| ALK/IGF1R inhibitor |
AZD3463 |
1356962-20-3 |
| Mutant IDH1-IN-1 |
MUTANT IDH1-IN-1 |
1355326-21-4 |
| Naloxegol Oxalate |
聚乙二醇纳诺醇 |
1354744-91-4 |
| WEHI-345 |
N-[2-[4-氨基-3-(4-甲基苯基)-1H-吡唑并[3,4-D]嘧啶-1-基]-2-甲基丙基]-4-吡啶甲酰胺 |
1354825-58-3 |
| (R)-4-(2-chloro-6-(((R)-methylsulfinyl)methyl)pyrimidin-4-yl)-3-methylmorpholine |
(R)-4-(2-chloro-6-(((R)-methylsulfinyl)methyl)pyrimidin-4-yl)-3-methylmorpholine |
1352227-16-7 |
| N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide |
化合物GSK503 |
1346572-63-1 |
| 2-(2H-benzo[b][1,4]oxazin-4(3H)-yl)-N-benzyl-5,6,7,8-tetrahydroquinazolin-4-amine |
ML241 |
1346528-06-0 |
| CEP-33779 |
N-[3-(4-甲基-1-哌嗪基)苯基]-8-[4-(甲磺酰基)苯基]-[1,2,4]三唑并[1,5-A]吡啶-2-胺 |
1346168-57-7 |
| LY-2795050 |
LY2795050 |
1346133-08-1 |
| Altiratinib |
ALTIRATINIB |
1345847-93-9 |
| PF-04554878 |
DEFACTINIB (VS-6063, PF-04554878) |
1345713-71-4 |
| GSK 2330672 |
GSK 2330672 |
1345982-69-5 |
